A prospective randomized controlled trial for the effect of m-hydroxylamine combined with dopamine and norepinephrine on hemodynamics in shock patients

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR1900023896

Enrollment

Unknown

Registered

2019-06-16

Start date

2019-05-15

Completion date

Unknown

Last updated

2019-06-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

shock

Interventions

Control group:Norepinephrine

Experimental group:Meta-hydroxylamine combined with dopamine

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: (1) Adult (Aged 18 to 80 years old); (2) Meet one of the following A + B: A: 1. The systolic blood pressure is lower than 80 mmHg; 2. The pulse pressure difference is less than 20mmHg; 3. In the original high blood pressure, the systolic blood pressure decreased by more than 30% compared with the original level. B: 1. Consciousness disorder; 2. HR>100 times/minute; 3. The limbs are pale and cold, the skin has spots, and the fingertip capillaries refill for more than 3 seconds; 4. The amount of urine is less than 0.5ml/kg; 5. Lactic acid>2mmol/l (3) Clear diagnosis of distributed shock

Exclusion criteria

Exclusion criteria: (1) Cannot satisfy two items in A + B at the same time; (2) non-shock patients, except for shock shock other types of shock; (3) There are severe tachyarrhythmia (fast atrial fibrillation > 160bpm, frequent room early, ventricular tachycardia).

Design outcomes

Primary

Measure	Time frame
28-day survival rate;	—

Countries

China

Contacts

Public ContactHuadong Zhu

Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College

huadongzhu@hotmail.com+86 13910696435

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026